28 August 2019 - The agenda for the November 2019 PBAC meeting is now available.

The PBAC will consider 56 submissions (28 major & 28 minor) at its next scheduled meeting in November.

42 (75%) are initial submissions.

15 (27%) of the 56 submissions are for a new medicine.

A quarter of all submissions are for oncology medicines.

Novartis and Roche are the leading applicants (4 submissions).

Of note:

• There is just one submission for a medicine for cardiovascular disease.  The number of submissions for medicines for cardiovascular disease has fallen considerably in recent times.
• The PBAC will consider another submission for a Herceptin biosimilar.  The PBAC has already considered (and recommended) four trastuzumab biosimilars.
• The PBAC will consider submissions for two CGRP receptor antagonists; erenumab (Aimovig) and fremanezumab (Ajovy).  The PBAC recently recommended Eli LIlly's CGRP rececptor antagnist galcanazumab (Emgality).

Read agenda for November 2019 PBAC meeting